Factors associated with knowledge, attitudes, and behaviors regarding antiviral medications for COVID-19 among US adults
PLOS One · 11.11.2025 · 20 (11) · e0335182
DOI: 10.1371/journal.pone.0335182 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 11.11.2025. Verfasst von E Ivy Oyegun und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America. Hauptthemen laut MEDLINE: Antiviral Agents, Health Knowledge, Attitudes, Practice, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).
Abstract (Originalsprache)
Background
Little is known about public perceptions of antivirals for the treatment of mild-to-moderate COVID-19 in the United States (US). Our objective was to explore adult perceptions toward COVID-19 antivirals to improve outreach communications about antivirals for COVID-19.
Methods
During July 2022, potential respondents ≥18 years were randomly sampled from a national opt-in internet panel, with oversampling of African Americans, Hispanics, and adults ≥65 years. Respondents were asked about sociodemographic factors, and knowledge, attitudes, and perceptions regarding COVID-19 antivirals. Results were weighted to represent the non-institutionalized US adult population.
Results
Among 1,155 respondents, 51% were female, 21% were 50−64 years, and 19% were ≥65 years. Compared to younger age groups, a greater proportion of adults ≥65 years were knowledgeable about COVID-19 antivirals and would take them if they tested positive or their doctor recommended them. Adults ≥65 years and those reporting immunosuppression or disability had the highest rates of willingness to take antivirals. For all groups, the proportion of people willing to take antivirals increased by >20% if recommended by their doctor. Respondents in the 50−64 and ≥65 groups who were sure they would take COVID-19 antivirals were more likely to be fully vaccinated and less likely to be living in isolation.
Conclusion
Groups that are less likely to have been vaccinated, those living in isolation, and those not sure about whether they would take an antiviral or not may be at risk for not receiving treatment to prevent severe COVID-19 outcomes. However, trust in doctor recommendations may be enough to overcome individual patient concerns about COVID-19 antivirals. Targeted initiatives to educate those at risk for severe COVID-19 outcomes about the effectiveness of antivirals may be needed to further lower this population’s risk of severe COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
- Tanaq Support Services, Anchorage, Alaska, United States of America.
- Emory University Rollins School of Public Health, Atlanta, Georgia, United States of America.
- KRC Research, Washington, DC, United States of America.
ORCID-Profile: E Ivy Oyegun
Zitieren
APA
Oyegun, E. I., Ategbole, M., Jorgensen, C., Fisher, A., Briggs Hagen, M., Gutekunst, L., Roberts, E., & Koumans, E. H. (2025). Factors associated with knowledge, attitudes, and behaviors regarding antiviral medications for COVID-19 among US adults. PLOS One, 20(11), e0335182. https://doi.org/10.1371/journal.pone.0335182
Vancouver
Oyegun EI, Ategbole M, Jorgensen C, Fisher A, Briggs Hagen M, Gutekunst L, et al. Factors associated with knowledge, attitudes, and behaviors regarding antiviral medications for COVID-19 among US adults. PLOS One. 2025;20(11):e0335182. doi:10.1371/journal.pone.0335182
BibTeX
@article{Oyegun2025,
author = {Oyegun, E Ivy and Ategbole, Muyiwa and Jorgensen, Cynthia and Fisher, Allison and Briggs Hagen, Melissa and Gutekunst, Lindsay and Roberts, Eric and Koumans, Emilia H},
title = {Factors associated with knowledge, attitudes, and behaviors regarding antiviral medications for COVID-19 among US adults},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {11},
pages = {e0335182},
doi = {10.1371/journal.pone.0335182}
}
EUVIMED